As a new-type foreign trade service provider driven by technological transformation and foreign trade business, HiSiaddi has established a "1+2+3+4=1" service system, and can supply Fmoc-8-amino-3,6-dioxaoctanoic acid (Semaglutide side chain intermediate) sourced from multiple well-known original manufacturers. With over a decade of market experience and technological transformation cooperation with manufacturers, HiSiaddi possesses extensive experience addressing product compliance issues. Below is the case handled by HiSiaddi regarding compliance risks of Fmoc-8-amino-3,6-dioxaoctanoic acid (Semaglutide side chain intermediate).
For inquiries regarding compliance issues of Fmoc-8-amino-3,6-dioxaoctanoic acid (Semaglutide side chain intermediate), please contact HiSiaddi customer service.
The client is Swiss Peptide AG, a high-end peptide pharmaceutical enterprise headquartered in Zurich, Switzerland, specializing in R&D and production of GLP-1 weight-loss drugs and oncology peptide drugs, supplying core European markets including Switzerland, Germany and France with an EMA/FDA dual-certified factory adhering to ICH Q7, EP 10.0 and USP 43 highest standards. The annual procurement volume of Fmoc-8-amino-3,6-dioxaoctanoic acid (Semaglutide side chain intermediate) for synthesis of high-end injectable APIs reaches 180kg, representing a pharmaceutical intermediate procurement scenario requiring top-tier compliance standards.
This is the client’s first procurement of this intermediate from China. Documents provided by contacted manufacturers failed to meet EMA and REACH requirements, triggering four major risks: missing qualifications, non-compliant documents, incomplete data and violating packaging & labeling standards. Goods faced detention upon port arrival, suspended production and delayed pharmaceutical registration risks, prompting the client to urgently entrust HiSiaddi with full-chain compliance rectification and customs clearance support.
After receiving client feedback, HiSiaddi immediately sorted out 6 fatal compliance defects directly breaching EU pharmaceutical and chemical regulatory red lines:
1. Missing Production Qualifications & Certifications Manufacturers only provided domestic GMP certificates without EU CEP certification, FDA DMF filing or EMA GMP audit reports; inability to issue NMPA export confirmation letters, violating EU Regulations on Imported Active Pharmaceutical Ingredients.
2. REACH Regulatory Compliance Gaps No completed REACH registration (SVHC Substances of Very High Concern testing); Safety Data Sheets (SDS) were outdated Chinese versions without English translations, CLP classification labels or exposure scenario assessments, violating EU REACH and CLP regulations.
3. Incomplete & Non-Standard Quality Document Data COAs only listed basic purity data without test results for single impurities/isomers/residual solvents/heavy metals/genotoxic impurities; missing analytical method validation reports, 3-batch 6-month accelerated stability data and impurity traceability reports, preventing passage of EMA audits.
4. Non-Compliant Labeling, Packaging & Transportation Goods packed in ordinary woven bags without light-proof/moisture-proof protection, hazard identification marks or unique batch traceability codes; labels printed solely in Chinese without English ingredient information, hazard warnings, production batch numbers or expiry dates, violating EU pharmaceutical packaging and dangerous goods transportation standards.
HiSiaddi formed a special team covering international pharmaceutical compliance, REACH registration, quality documentation and hazardous goods logistics, completing full-process rectification within 7 days to guarantee 100% alignment of documents, qualifications, packaging and transportation with EMA/REACH standards.
Cooperated with partner GMP factories to expedite NMPA export confirmation letters, simultaneously submit pre-applications for EU CEP certification, and provide zero-defect FDA cGMP audit reports and EMA on-site audit passing certificates from the past three years. Assisted manufacturers in completing official REACH registration, commissioning EU SGS laboratories to issue test reports covering 224 SVHC substances, confirming all substances below limit values with no carcinogenic or teratogenic risks. Supplied DMF filing Letters of Authorization (LOA), allowing the client to directly reference factory FDA DMF registration numbers (e.g., Nuota Biotech DMF 041314) for pharmaceutical registration applications.
1. Revised English COAs: Compiled in accordance with EP 10.0 standards, supplemented with full-item data including HPLC purity ≥99.7%, single impurity ≤0.05%, water content ≤100ppm, residual solvents ≤500ppm, heavy metals ≤10ppm and undetected genotoxic impurities, paired with chromatograms and mass spectra for each batch.
2. Core Technical Document Package: Compiled English production process flowcharts, impurity analysis reports, analytical method validation reports, 3-batch 6-month accelerated stability reports and material traceability certificates with fully traceable and reproducible data.
3. REACH Compliance Documents: Issued 16-section English SDS, CLP classification labels, exposure scenario assessment reports and supply chain compliance statements, clarifying non-dangerous goods classification, standard operating procedures and storage & transportation conditions.
1. Packaging Upgrade: Replaced with thickened vacuum aluminum foil bags plus light-proof moisture-proof hard cartons with built-in desiccants and inert gas sealing to prevent degradation and moisture absorption during transportation and storage.
2. Standardized Labeling: Redesigned English labels containing product name, CAS number, batch number, purity, net weight, manufacturer, expiry date, hazard warnings, storage conditions and traceability QR codes, complying with EU pharmaceutical packaging and CLP regulations.
3. Batch Traceability: Established unique batch traceability codes linked to production records, test reports, stability data and logistics information to realize full-lifecycle traceability compliant with FDA Access Data requirements.
1. Hazardous Goods Classification: Issued non-dangerous goods identification reports to enable transportation as ordinary chemicals, avoiding expensive hazardous goods freight and special supervision.
2. Pre-Audit of Customs Clearance Documents: Pre-reviewed commercial invoices, packing lists, bills of lading, COAs, SDS, certificates of origin and REACH registration certificates to ensure consistent, complete and error-free data.
3. Customs Liaison: Provided English compliance explanation letters to coordinate verification of documents and goods with Swiss customs, enabling 24-hour expedited customs clearance without detention or fines.
1.
Full Set of Compliance Documents Pass EMA Audit at One Go Revised full English document packages (COAs, spectra, stability data, SDS, qualification certificates) passed the client’s EMA internal audit without supplementary information requests, directly applicable for pharmaceutical registration applications and EMA quarterly sampling inspections.
2.
3.
Smooth Customs Clearance & Zero-Risk Production Launch The first 80kg batch completed customs clearance within 24 hours upon port arrival without detention, fines or inquiries. Upon unpacking inspection, intact packaging, standardized labels and non-degraded materials with test data consistent with COAs allowed direct production launch without one day of delay.
4.
5.
Long-Term Compliance Safeguards to Mitigate Follow-Up Risks HiSiaddi pre-audits full compliance documents before each shipment to guarantee 100% alignment with EMA/REACH standards. A dynamic compliance tracking mechanism was established to update EU regulatory revisions in real time and issue early warnings of compliance risks. Annual compliance audit services are provided to assist clients with EMA/FDA on-site inspections.
6.
7.
Client Evaluation & Deepened Cooperation The client’s compliance director offered high recognition: “HiSiaddi not only resolved the immediate customs detention crisis, but also helped us build a complete Chinese supply chain compliance system covering qualifications, documents, packaging and transportation, fully aligned with the highest European and American standards. It delivers professional, efficient and trustworthy services.”
8.
A three-year long-term supply agreement was signed between both parties, and the client entrusted HiSiaddi with full supply and compliance management for all GLP-1 side chain intermediates and protected amino acids, designating HiSiaddi as its exclusive compliance supplier in China.
Compliance is the lifeline for European and American high-end pharmaceutical enterprises purchasing Fmoc-8-amino-3,6-dioxaoctanoic acid, with zero tolerance under regulations including EMA, REACH, CLP and ICH Q7. Domestic manufacturers frequently face export barriers due to missing international qualifications, non-standard documents, incomplete data and non-compliant packaging, while overseas clients lack experience with Chinese compliance frameworks and easily encounter risks including customs detention, suspended production and delayed registration.
HiSiaddi’s core advantage lies in in-depth understanding of European and American pharmaceutical and chemical regulations with full-cycle compliance rectification capabilities. It can rapidly supplement international qualifications, reconstruct compliance documents, upgrade packaging and labels, and guide compliant customs clearance to resolve all compliance pain points in one go, helping overseas mid-to-high-end clients mitigate compliance risks, secure stable supply chains and accelerate pharmaceutical launch timelines, continuously strengthening the compliance competitiveness of domestic high-end pharmaceutical intermediates in high-end European markets.
For inquiries regarding compliance issues of Fmoc-8-amino-3,6-dioxaoctanoic acid (Semaglutide side chain intermediate), please contact HiSiaddi customer service.
+86-13120989737 
info@hisiaddi.com 
English
